CO-FOUNDER AND CHAIRMAN OF THE BOARD

Co-Founder of AirXpanders® and Chairman of the Board

Over 25 years of experience, primarily in the general management of medical device enterprises in the US

Three-time medical device company CEO, having taken one company public (RITA Medical) and sold another (NanoGram Devices) to its competitor (Wilson Greatbatch) one year into his tenure

RITA Medical developed and marketed a minimally invasive radio frequency ablation device used for cancer treatment.

NanoGram Devices developed novel medical batteries based on a proprietary nanomaterials technology, with their first application directed at implantable defibrillators.

Currently President and CEO of the medical device company PowerVision, Inc.

Holds degrees in Mechanical Engineering from MIT (BS) and Stanford (MS), as well as an MBA from Columbia Business School

President and CEO of AirXpanders since 2010—responsible for the overall management and strategic direction of the Company

Holds over 25 years of driving results in companies throughout the medical device industry via various executive management and leadership positions

June 1996 to December 2000: Led the international expansion of The Boston Scientific Corp., a multi-billion dollar global company with diverse product holdings in cardiology, rhythm management, vascular, electrophysiology, endoscopy and women’s health. He held significant roles in sales, marketing, operations, business development, and market development in the Endoscopy and Women’s Health business groups of the company, which represented over US$2 billion in annual revenue.

May 2004 to March 2007: President of Global Orthopedics and President of International at Orthofix Orthopedics, for the company’s spine, orthopedic, and sports medicine business groups.

March 2007 to August 2007: Served at BarrX Medical, a California-based gastroenterology start-up for pre-cancerous treatment of the oesophagus, which was later sold to Covidien for US $340 million.

August 2007 to August 2010: Mr. Dodson was the President and CEO of Avantis Medical, a California-based gastroenterology medical device start-up.

BS in Management from Indiana University in Bloomington, Indiana; Executive Management Programs of both Columbia University and Babson College

CO-FOUNDER AND BOARD MEMBER

Co-Founder of AirXpanders® and the Chief Executive Officer and sole shareholder of Shalon Ventures, an evergreen life science and technology incubator funded by the Shalon family

An accomplished entrepreneur, executive, and investor focusing on life science-oriented ventures, with 30 years of experience in medical device and medical product development in privately held companies such as Renew Medical, Airflow Medical, ThinOptics, Guard Medical, and Theracaine

Founded and sold, in private transactions, several life sciences companies over the course of his career, including Osteogenix (sold to Medtronics), Synteni (sold to Incyte Pharmaceuticals), and Ivy Technologies (sold to Alcon)

MS in Computer Science, BA in Physics, and a BS in Electrical Engineering from Washington University in St Louis, US.

FORMER PRESIDENT & CEO OF MERZ AESTHETICS, INC. & AT LARGE BOARD MEMBER

Chairman of the Audit and Risk Committee and Member of the Remuneration and Nomination Committee

CEO and President of Nuvesse Skin Therapies, a venture-backed cosmeceutical skincare company that has launched 12 products into the US medical device market

Former CEO and President of Merz Aesthetics, Inc. (from September 2011 to January 2013), after serving as President and Chief Business Officer from July 2007 and a board member from 2004 to 2007, also former CEO of BioForm Medical (acquired by Merz Aesthetic for US$250 million).

Carries 30 years of experience in key executive roles in the plastic surgery market, including serving as the President and CEO of Mentor Aesthetics, one of the two largest global breast implant manufacturers

Mr Lichtwardt was appointed Non-Executive Director of the Company in April 2016.
Mr Lichtwardt most recently held the position of Executive Vice President, Operations and Chief Financial Officer at Accuray, a NASDAQ-listed radiation company that develops, manufactures and sells innovative tumor treatment solutions. At Accuray, Mr Lichtwardt had responsibility over finance, treasury, investor relations, manufacturing, supply chain and facilities functions.
Mr Lichtwardt was previously a Director at Biolase Inc, a US-based, NASDAQ-listed medical device company that develops, manufactures, markets and sells laser systems and dental imaging equipment in dentistry. At Biolase, he held the position of Audit Committee Chair and Quality Committee Chair and was a member of the Compensation Committee.
Prior to this, Mr Lichtwardt was the Executive Vice President, Operations and Chief Financial Officer at Conceptus Inc, a company which designs, develops, and markets minimally invasive devices for reproductive medical applications. During his time at Conceptus, its sales grew from US$8 million to US$141 million and adjusted EBITDA reached 20 percent of sales.
Mr. Lichtwardt holds a BBA degree from the University of Michigan and an MBA degree from Michigan State University.

Ms Peach was appointed Non-Executive Director of the Company in April 2016.
Ms Peach’s most recent executive position was as the Managing Director for Australia and New Zealand and Executive Vice President, South Asia Pacific for Frensenius Kabi, a provider of pharmaceutical products and medical devices to hospitals. She played a key role in the sustained development of the company in the Asia Pacific region, achieving double-digit growth and becoming the fastest growing region, contributing around 30% of total company revenue.
Previously, Ms Peach was Vice President of Business Development at CSL Limited, a top 20 ASX biopharmaceutical company focused on developing and marketing protein therapeutics for serious unmet medical diseases.
In 2015, Ms Peach joined the board of two early stage medical technology companies: 4Dx, a company involved in commercialising four-dimensional lung imaging technology; and Bionic Vision Technology, a developer of visual prostheses for patients with retinal degeneration conditions.
Ms Peach currently serves as a Non-Executive Director of Starpharma Holdings, an ASX300 company and a leader in the development of dendrimer products for pharmaceutical, life science and other applications. She also serves on the board of the Vision Eye Institute, Australia’s leading provider of ophthalmic service
Ms Peach holds a Bachelor of Science from the University of Melbourne, and is a graduate of the Australian Institute of Company Directors. She is a Fellow at the Australian Institute of Marketing, and a member of both Women on Boards and the Australian Institute of Company Directors.